PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
Visit https://www.peervoice.com/VVA860 to view the entire programme with slides. After completing “Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC”, participants will be able to: Describe the unmet needs for patients with advanced NSCLC and how checkpoint inhibitors can address these challenges; Evaluate the most recent clinical evidence for current and emerging checkpoint inhibitors in the first-line management of advanced NSCLC with high PD-L1 expression; Discuss how emerging data may impact the treatment algorithm for patients with advanced NSCLC and high PD-L1 expression.